Top Stories
The suite includes the CE-marked LiverPRO algorithm, which assesses fibrosis risk using only age and routine blood markers.
Doctronic's system recommended renewal in 72% of cases, with physicians agreeing in 91% of those reviews.
The MRD test detected recurrence a median of 13.8 months before clinical progression, with lead times reaching nearly four years in the NeoCircle study.
The digital symptom monitoring platform supports real-time toxicity reporting to healthcare teams via a red, amber and green triage system.
The startup's robot is cleared for use in procedures covering general surgery, gynaecology, thoracic surgery and urology.
Conference News
Leading neurologists, researchers, and clinicians gather June 4–7, 2026 for the premier scientific conference in headache medicineMOUNT ROYAL, N.J.--(BUSINESS WIRE)-- A new class of migraine treatment...
May 26, 2026Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy DecisionsLatest findings from the BCI Registry Stu...
This is the first noninvasive, AI-powered tool that provides a critical heart pressure reading for patients with heart failureCHICAGO--(BUSINESS WIRE)-- Cardiosense, a healthcare technology company fo...
CARLSBAD, Calif.--(BUSINESS WIRE)-- Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced that it will pr...
REDWOOD CITY, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the 2026 A...
